CD8A and breast cancer: Furthermore, exomiR-149-3p reduces inhibitory receptors and revised CD8+ T cell exhaustion in breast cancer cells (Zhang et al., 2019), and exomiR-5119 enhance BC immunotherapy through regulation of immune checkpoints in dendritic cells (Zhang et al., 2020b).